{"type":"trials","record":{"id":31334,"source_id":"clinicaltrials-gov","external_id":"NCT06813261","title":"GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women","brief_summary":"The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Buck Institute for Research on Aging","enrollment":30,"countries":["United States"],"start_date":"2025-04-01","completion_date":"2026-06-30","last_update_date":"2025-09-08","source_url":"https://clinicaltrials.gov/study/NCT06813261","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:21.317971+00:00","last_seen_at":"2026-09-25T06:15:13.984+00:00","metadata":{"sex":"FEMALE","acronym":"GRACE","age_range":"45 Years to 65 Years","comparator":"Placebo","organization":"Buck Institute for Research on Aging","interventions":["GLYLO","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Methylglyoxal (MGO) — Baseline, Week 12, Week 24","Advance glycation end products (AGE) — Baseline, Week 12, Week 24","Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) — Baseline, Week 12, Week 24","HbA1c — Baseline, Week 12, Week 24","Body fat — Baseline, Week 12, Week 24","Body mass index (BMI) — Baseline, Week 12, Week 24","Hip circumference — Baseline, Week 12, Week 24","Follicle-stimulating hormone (FSH) — Baseline, Week 12, Week 24","Muscle mass — Baseline, Week 12, Week 24","Waist circumference — Baseline, Week 12, Week 24"],"design_description":"RANDOMIZED · PARALLEL · OTHER · TRIPLE","source_has_results":false},"controlled_terms":["Postmenopause","Metabolism","Geroscience","GLYLO","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: glycation.","quality_checked_at":"2026-09-25T06:15:15.562724+00:00","duplicate_cluster_key":"id:nct06813261","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-04-01 to 2026-06-30","comparator":"Placebo","confidence":"structured-source","population":"FEMALE · 45 Years to 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:14.002Z","intervention":["GLYLO","Placebo"],"participants":30,"study_design":"RANDOMIZED · PARALLEL · OTHER · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Methylglyoxal (MGO) — Baseline, Week 12, Week 24","Advance glycation end products (AGE) — Baseline, Week 12, Week 24","Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) — Baseline, Week 12, Week 24","HbA1c — Baseline, Week 12, Week 24","Body fat — Baseline, Week 12, Week 24","Body mass index (BMI) — Baseline, Week 12, Week 24","Hip circumference — Baseline, Week 12, Week 24","Follicle-stimulating hormone (FSH) — Baseline, Week 12, Week 24","Muscle mass — Baseline, Week 12, Week 24","Waist circumference — Baseline, Week 12, Week 24"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"glycation-ages","is_published":true,"match_reasons":["Title contains controlled term: glycation.","Abstract contains controlled term: advanced glycation end product, glycation.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Glycation and AGEs","slug":"glycation-ages"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/31334","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}